Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1341-1349

  Siddiqi, Laima ^a   Joles, Jaap A ^a   Grassi, Guido ^b   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Angiotensin converting enzyme inhibition; Angiotensin II antagonism; Angiotensin II receptor blockade; Chronic kidney disease; Kidney ischemia; Renin angiotensin aldosterone system; Sympathetic nerve activity

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ATENOLOL; BENAZEPRIL; CANDESARTAN; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FELODIPINE; LERCANIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; MIBEFRADIL; PRAZOSIN; QUINAPRIL; RENIN; SPIRONOLACTONE; URAPIDIL; VALSARTAN;

ADRENERGIC SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; KIDNEY ISCHEMIA; METABOLIC SYNDROME X; NERVE CONDUCTION; NORADRENALIN BLOOD LEVEL; OBESITY; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; WEIGHT REDUCTION;

EID: 67649755209     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832b521b     Document Type: Review

References (108)

1. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979; 59:919-957.
2. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17:719-734.
3. Schalekamp MA, Schalekamp-Kuyken MP, de Moor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, Birkenhager WH. Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 1973; 45:417-428.
4. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19:1354-1357.
5. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706.
6. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:524-537.
7. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568-1576.
8. Blankestijn PJ, Ligtenberg G, Klein IH, Koomans HA. Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance. Nephrol Dial Transplant 2000; 15:755-758.
9. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2:349-359.
10. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H, et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 1991; 261:R690- 696.
11. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008; 51:727-733.
12. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294:H1067- H1074.
13. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11:723-728.
14. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 2000; 75:S2-6.
15. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25:878-882.
16. Hendel MD, Collister JP. Renal denervation attenuates long-term hypertensive effects of Angiotensin ii in the rat. Clin Exp Pharmacol Physiol 2006; 33:1225-1230.
17. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, et al.Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006; 103:17985- 17990.
18. Wenting GJ, Blankestijn PJ, Poldermans D, van Geelen J, Derkx FH, Man in't Veld AJ, et al. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol 1987; 59:92D-97D.
19. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad- Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
20. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation2002; 106:1974-1979.
21. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
22. Tinucci T, Abrahao SB, Santello JL, Mion D Jr. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15:401-406.
23. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430.
24. Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, et al.Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49:506-510.
25. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15:2902-2907.
26. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244.
27. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99:2537-2542.
28. Morlin C, Fagius J, Hagg A, Lorelius LE, Niklasson F. Continuous recording of muscle nerve sympathetic activity during percutaneous transluminal angioplasty in renovascular hypertension in man. J Hypertens1990; 8:239-244.
29. Petersson MJ, Rundqvist B, Johansson M, Eisenhofer G, Lambert G, Herlitz H, et al. Increased cardiac sympathetic drive in renovascular hypertension. J Hypertens 2002; 20:1181-1187.
30. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17:1057-1062.
31. Converse RL Jr, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992; 90:1657-1665.
32. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31:68-72.
33. Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al.Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 2007; 25:157-161.
34. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al.Adverse mortality effect of central sympathetic inhibition with sustainedrelease moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5:659-667.
35. Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, et al.Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007; 25:1285-1289.
36. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Jensen G, et al. Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension. Hypertension2000; 36:543-548.
37. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368:1449-1456.
38. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005; 45:522-525.
39. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006; 69:967-973.
40. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic Activation in Chronic Renal Failure. J Am Soc Nephrol 2008. [Epub ahead of print]
41. Strand AH, Gudmundsdottir H,Os I, Smith G, Westheim AS, Bjornerheim R, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens 2006; 24:905- 913.
42. Veelken R, Vogel EM, Hilgers K, Amann K, Hartner A, Sass G, et al.Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19:1371-1378.
43. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, et al. Norepinephrine and concentric hypertrophy in patients with endstage renal disease. Hypertension 2002; 40:41-46.
44. Penne ELNJ, Oey PL, Bots ML. Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22:208-215.
45. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5:86-99.
46. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14:177-183.
47. Esler M, Lambert G, Jennings G. Increased regional sympathetic nervous activity in human hypertension: causes and consequences. J Hypertens Suppl 1990; 8:S53-S57.
48. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998; 31:64-67.
49. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989; 13:870-877.
50. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711-1717.
51. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation1999; 100:1305-1310.
52. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, et al.Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14:1357-1364.
53. Schlaich MP, Kaye DM, Lambert E, Hastings J, Campbell DJ, Lambert G, et al. Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 2005; 23:1077-1082.
54. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
55. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007; 115:1999-2005.
56. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26:381-391.
57. Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 1997; 15:1613-1619.
58. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension1988; 11:608-612.
59. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998; 16:1789-1796.
60. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens 2007; 25:169-175.
61. Struck J, Muck P, Trubger D, Handrock R, Weidinger G, Dendorfer A, et al. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002; 20:1143-1149.
62. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558-562.
63. Bechir M, Enseleit F, Chenevard R, Luscher TF, Noll G. Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension. Am J Cardiol 2005; 95:129-131.
64. Wallin BG, Frisk-Holmberg M. The antihypertensive mechanism of clonidine in man. Evidence against a generalized reduction of sympathetic activity. Hypertension 1981; 3:340-346.
65. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol2006; 290:H1706-H1712.
66. Sakata K, Yoshida H, Obayashi K, Ishikawa J, Tamekiyo H, Nawada R, et al. Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 2002; 20:103-110.
67. Burns J, Mary DA, Mackintosh AF, Ball SG, Greenwood JP. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension 2004; 44:454- 458.
68. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension1984; 6:557-562.
69. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al.Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
70. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73:615-621.
71. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93:1667-1676.
72. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23:570-578.
73. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997; 95:169-175.
74. Leimbach WNJr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73:913-919.
75. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92:3206-3211.
76. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003; 42:873-877.
77. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension2007; 49:535-541.
78. Grassi G, Giannattasio C, Cuspidi C, Bolla GB, Cleroux J, Ferrazzi P, et al.Cardiopulmonary receptor regulation of renin release. Am J Med 1988; 84:97-104.
79. Grassi G, Giannattasio C, Saino A, Sabadini E, Capozi A, Sampieri L, et al.Cardiopulmonary receptor modulation of plasma renin activity in normotensive and hypertensive subjects. Hypertension 1988; 11:92-99.
80. Spaak J, Egri ZJ, Kubo T, Yu E, Ando S, Kaneko Y, et al. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea. Hypertension 2005; 46:1327-1332.
81. Amsalem Y, Garty M, Schwartz R, Sandach A, Behar S, Caspi A, et al.Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. Eur Heart J 2008; 29:1029-1036.
82. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96:1173-1179.
83. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005; 45:661-667.
84. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med1997; 38:1085-1089.
85. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003; 44:884- 890.
86. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002; 43:1279-1285.
87. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574-581.
88. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, et al.Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001; 104:2194-2199.
89. Rahman MA, Hara K, Daly PA, Wigle ED, Floras JS. Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations. Br Heart J 1995; 74:431- 436.
90. Grassi G, Spaziani D, Seravalle G, Bertinieri G, Dell'Oro R, Cuspidi C, et al. Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Hypertension 1999; 33:671-675.
91. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97:2037- 2042.
92. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34:724-728.
93. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension 2001; 38:286-291.
94. Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, et al.Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007; 48:1993-2000.
95. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al.Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007; 28:989-995.
96. De Matos LD, Gardenghi G, Rondon MU, Soufen HN, Tirone AP, Barretto AC, et al. Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. J Card Fail 2004; 10:496-502.
97. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens2007; 25:909-920.
98. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22:2363-2369.
99. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, et al.Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46:321-325.
100. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25:560-563.
101. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
102. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44:12-19.
103. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al.Weight loss and the renin-angiotensin-aldosterone system. Hypertension2005; 45:356-362.
104. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
105. Norman JT, Stidwill R, Singer M, Fine LG. Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003; 94:39-46.
106. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al.Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16:3631-3641.
107. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, et al.Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15:1277-1288.
108. Schachinger H, Klarhofer M, Linder L, Drewe J, Scheffler K. Angiotensin II decreases the renal MRI blood oxygenation level-dependent signal. Hypertension 2006; 47:1062-1066.